Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 10/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4503136 | 0.90 | CYP11B2 (0.46) | CYP11B2CYP11B1CYP3A4ALDH1A1POLB | |
| SCHEMBL3979450 | 0.89 | CYP11B1 (0.47) | CYP11B2CYP11B1CYP3A4GRM2 | |
| SCHEMBL3979552 | 0.89 | CYP11B2 (0.45) | CYP11B2CYP11B1CYP3A4ALDH1A1POLB | |
| SCHEMBL4093776 | 0.88 | CYP11B1 (0.41) | CYP11B2CYP11B1CYP3A4ALDH1A1HTT | |
| SCHEMBL3982570 | 0.87 | CYP11B2 (0.41) | CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL4512559 | 0.85 | CYP11B2 (0.63) | CYP11B2CYP11B1 | |
| SCHEMBL3974100 | 0.82 | CYP11B2 (0.49) | CYP11B2CYP11B1CYP3A4ALDH1A1POLB | |
| SCHEMBL3975895 | 0.81 | CYP11B2 (0.53) | CYP11B2CYP11B1CYP3A4ALDH1A1POLB | |
| SCHEMBL3977072 | 0.81 | CYP11B2 (0.47) | CYP11B2CYP11B1CYP3A4ALDH1A1POLB | |
| SCHEMBL3982940 | 0.80 | CYP11B2 (0.47) | CYP11B2CYP11B1ALDH1A1POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264420-A1 | ORGANIC COMPOUNDS | KSANDER GARY MICHAEL | 2009-10-22 | — | — | US | disclosed |
| US-20090264420-A1 | ORGANIC COMPOUNDS | KSANDER GARY MICHAEL | 2009-10-22 | — | — | US | disclosed |
| US-20090264420-A1 | ORGANIC COMPOUNDS | KSANDER GARY MICHAEL | 2009-10-22 | — | — | US | disclosed |
| EP-2057163-A1 | FUSED IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY ALDOSTERONE SYNTHASE AND/OR 11-BETA-HYDROXYLASE AND/OR AROMATASE | Novartis AG (CH) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008027284-A1 | FUSED IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY ALDOSTERONE SYNTHASE AND/OR 11-BETA-HYDROXYLASE AND/OR AROMATASE | NOVARTIS AG (CH) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008027284-A1 | FUSED IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY ALDOSTERONE SYNTHASE AND/OR 11-BETA-HYDROXYLASE AND/OR AROMATASE | NOVARTIS AG (CH) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264420-A1 | ORGANIC COMPOUNDS | CYP17A1, CYP11B1, CYP46A1 | CYP11B2 11/4885CYP11B1 2/4885CYP3A4 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.